Navigation Links
Appointment of Mr. Kevin Buchi to Benitec Board
Date:4/11/2013

SYDNEY, April 10, 2013 /PRNewswire/ -- Benitec Biopharma Ltd (ASX: BLT), a biopharmaceutical company developing innovative therapeutics based on its gene silencing technology, DNA-directed RNA interference (ddRNAi), is very pleased to report that Mr. Kevin Buchi , CPA, has accepted an invitation to join the Company's Board of Directors. 

Mr. Buchi served as Chief Executive Officer of Cephalon, Inc. through its $6.8 billion acquisition by Teva Pharmaceutical Industries in October 2011. After the acquisition Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer, Chief Financial Officer and Head of Business Development prior to being appointed CEO.

Mr. Buchi currently serves on the Board of Directors of Stemline Therapeutics, Inc., Forward Pharma A/S and Alexza Pharmaceuticals, Inc. Mr. Buchi has served on the Board of Directors of Lorus Therapeutics (Canada), Encysive Pharmaceuticals, Inc., Celator Pharmaceuticals, Inc. and Mesoblast Limited (Australia). Mr. Buchi has served as a Member of the Life Sciences Advisory Board at Safeguard Scientifics, Inc.

Mr. Buchi originally trained as a synthetic organic chemist for the Eastman Kodak Company graduating from Cornell University with a Bachelor of Arts degree in chemistry. He holds a Master's degree in management from the Kellogg Graduate School of Management at Northwestern University and is a Certified Public Accountant. He resides in Pennsylvania in the United States.

Benitec Biopharma's Chairman, Mr. Peter Francis , welcomed Mr Buchi's appointment. "Kevin's impressive track record in the international biotechnology and pharmaceutical industry over 30 years provides Benitec with significant additional business development strength, and importantly, networking capacity in the United States and Europe. The Directors and Management look forward to working closely with Kevin to achieve the Company's aims through industry partnerships. We see this as a validation of Benitec's corporate strategy over the past few years."

Mr. Buchi commented, "I continue to be impressed with Benitec's programs and progress. The expected entry of the Company's Hepatitis C therapy into the clinic later this year is validation of that progress.  I believe that Benitec Biopharma's technology and programs have the potential to bring about a revolution in treatment of many diseases and conditions through the power of DNA-directed RNA interference. I look forward to working with the Company to help advance its exciting programs and vision."

For more information please contact:
Dr. Peter French | Chief Executive Officer
Phone: +61 (02) 9555 6986 | pfrench@benitec.com | www.benitec.com

About Benitec Biopharma Limited:
Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.


'/>"/>
SOURCE Benitec Biopharma Limited
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. National Honey Board Seeks Board Member Nominees: Appointments to be Made by United States Secretary of Agriculture
2. TaxOps Announces Partner Appointment to Prominent International Position with Fortune 100 Company
3. Store-A-Tooth™ Stem Cell Banking Announces Appointment of Dedicated Sales Representative in New England
4. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
5. PharmaDirections Announces Appointment of Dr. Bruce Rehlaender as Principal, Formulation Development
6. Mobility and Big Data Analytics Provider NuWare Announces the Appointment of Rohit Shyam as Chief Strategy & Marketing Officer
7. Store-A-Tooth™ Dental Stem Cell Banking Announces Appointment of Dedicated Representative in South Florida
8. Sequenom Announces Leadership Appointments
9. T1D Exchange Announces Appointment of Dana Ball as Chief Executive Officer
10. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
11. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... The Real Dirt ... premier cannabis technology and application experts, Chip Baker. Chip Baker formerly co-founded Royal ... the past 30 years, Chip Baker other industry veterans have made the evolution ...
(Date:12/5/2016)... CHICAGO , December 5, 2016 ... report, "Cell Expansion Market, by Products (Consumable, Instruments, ... Applications (Regenerative Medicine and Stem Cell Research, Cancer, ... Research Institutes, Cell Banks) - Global Revenue, Trends, ... by Scalar Market Research, the global cell expansion ...
(Date:12/5/2016)... - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) ... Monitoring Board (DSMB) for the Company,s Phase 3 ... has completed a second planned safety review and ... without any modifications. The DSMB reviewed available study ... concerns were identified. The DSMB will conduct additional ...
(Date:12/5/2016)... Dec. 5, 2016  Eisai Inc. announced today ... study of rufinamide, which were presented at the ... (AES) held from December 2-6 in ... safety, tolerability and cognitive data showed that patients ... safety and tolerability profiles, cognitive development and behavior, ...
Breaking Biology Technology:
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
Breaking Biology News(10 mins):